2025-523995-21-00招募中1 期
A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 42
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
AstraZeneca Clinical Study Information Center
Scientific
AstraZeneca AB
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2− Breast Cancer (CAPItello-291)2023-505042-25-00AstraZeneca AB366
招募中
1 期
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLLymphomaLeukemiaNCT07294677University of Chicago104
撤回
1 期
A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors2024-516611-24-00AstraZeneca AB18
招募中
3 期
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentBreast CancerMetastatic Breast CancerAdvanced Breast CancerNCT07281833Women's Cancer Study Group GmbH250
招募中
不适用
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerNCT07347600Hoffmann-La Roche500